Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment
PMCID: PMC12175699
PMID: 40526090
DOI: 10.18632/oncotarget.28744
Journal: Oncotarget
Publication Date: 2025
Authors: Hernando-Calvo A, Kurzrock R, Gonzalez NS, Magidi S, Bresson C, et al.
Key Points
- Comprehensive molecular profiling revealed multiple actionable genetic alterations in mCRC
- Personalized treatment strategies proposed, including targeted therapies matching specific mutations
- Repeated molecular testing (tissue and liquid biopsy) is crucial for tracking tumor evolution and identifying emerging resistance mechanisms
Summary
This case report highlights the complex management of heavily pretreated metastatic colorectal cancer (mCRC) through comprehensive molecular profiling and personalized therapeutic strategies. The patient, a 62-year-old male with multiple genetic alterations (BRAF, MET, APC, TP53, NRAS), underwent multiple treatment lines with progressively diminishing responses, demonstrating the challenging nature of advanced mCRC.
The WIN International Molecular Tumor Board (MTB) employed a sophisticated approach of analyzing molecular alterations to propose targeted treatment combinations. Despite limited clinical trial availability, the experts recommended personalized strategies such as amivantamab-vmjw, trametinib, and regorafenib, tailored to the patient's specific genetic profile. This approach underscores the critical importance of comprehensive genomic testing and adaptive treatment planning in managing complex cancer cases with multiple molecular drivers.